Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study - 12/05/21
Doi : 10.1016/j.jinf.2021.02.011
Jaime Lora-Tamayo a, ⁎ 
, Guillermo Maestro a, Antonio Lalueza a, Manuel Rubio-Rivas b, Gracia Villarreal Paul c, Francisco Arnalich Fernández d, José Luis Beato Pérez e, Juan Antonio Vargas Núñez f, Mónica Llorente Barrio g, Carlos Lumbreras Bermejo a
, Guillermo Maestro a, Antonio Lalueza a, Manuel Rubio-Rivas b, Gracia Villarreal Paul c, Francisco Arnalich Fernández d, José Luis Beato Pérez e, Juan Antonio Vargas Núñez f, Mónica Llorente Barrio g, Carlos Lumbreras Bermejo afor the SEMI-COVID-19 Network
a Internal Medicine Department, 12 de Octubre University Hospital, Research Institute Hospital 12 de Octubre “i+12 Institute”, Madrid, Spain
b Internal Medicine Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain
c Internal Medicine Department, Gregorio Marañon University Hospital, Madrid, Spain
d Internal Medicine Department, La Paz University Hospital, Madrid, Spain
e Internal Medicine Department, Albacete University Hospital Complex, Albacete, Spain
f Internal Medicine Department, Puerta de Hierro University Hospital, Majadahonda (Madrid), Spain
g Internal Medicine Department, Miguel Servet Hospital, Zaragoza, Spain
⁎Corresponding author at: Hospital Univ. 12 de Octubre. Servicio de Medicina Interna (Planta 13). Avda. Córdoba s/n. 28041 Madrid, Spain.Hospital Univ. 12 de OctubreServicio de Medicina Interna (Planta 13)Avda. Córdoba s/n.Madrid28041Spain
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | This is the largest study assessing the efficacy of LPV/r against SARS-CoV-2. |
• | The overall use of LPV/r was not associated with lower mortality in CoVID19 patients. |
• | The early use of LPV/r (median 5 days) showed no benefit either. |
Plan
| A complete list of the SEMI-COVID-19 Network members is provided in the Appendix. |
© 2021
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 82 - N° 6
P. 276-316 - juin 2021 Retour au numéro
Article précédent
- Decrease in norovirus infections in Germany following COVID-19 containment measures
- Ulrich Eigner, Thomas Verstraeten, John Weil
- Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study
- Jean-Philippe Kevorkian, Amanda Lopes, Damien Sène, Jean-Pierre Riveline, Claire Vandiedonck, Florine Féron, Kladoum Nassarmadji, Stéphane Mouly, Franck Mauvais-Jarvis, Jean-François Gautier, Bruno Mégarbane
Bienvenue sur EM-consulte, la référence des professionnels de santé.